UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-42392 INFLECTION POINT ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) Cayman Islands 98-1797826 (State or other juris ...

IPO and Business Combination - The company completed its IPO on November 4, 2024, raising gross proceeds of $250 million by selling 25 million units at $10.00 per unit[20]. - A total of $250 million from the IPO proceeds was placed in a trust account, which will not be released until certain conditions are met, including the completion of a business combination[22]. - The company entered into a Business Combination Agreement with Merlin Labs, Inc. on August 13, 2025, which includes a merger and a change of jurisdiction to Delaware[25]. - The aggregate consideration for the merger is set at $800 million, divided by the redemption price of the Public Shares[31]. - The Proposed Business Combination is expected to be consummated on March 16, 2026, following the requisite shareholder approval received on March 12, 2026[44][45]. - The company plans to change its name to "Merlin, Inc." following the completion of the business combination[25]. - The company will provide Public Shareholders the opportunity to redeem their shares prior to the Domestication[27]. - The company has raised approximately $78 million through convertible promissory notes and warrants as part of the financing for the business combination[29]. - The management team underwent changes in July 2025, with new appointments for key executive positions[23]. - The Company and Merlin entered into a Series A Preferred Stock investment agreement, with the Closing PIPE Investor increasing its investment to $100 million for 9,803,922 shares at a price of $10.20 per share[41]. - An additional investment of $20 million was secured from Additional Closing PIPE Investors for 1,666,668 shares of Series A Preferred Stock at $12.00 per share[42]. Shareholder Rights and Redemption - The company will convert each outstanding Class A Ordinary Share into shares of New Merlin Common Stock upon completion of the merger[28]. - Public Shareholders are entitled to redeem their shares for cash at a price of $10.00 per Public Share if the initial business combination is not completed by March 10, 2025[91]. - The per-share redemption amount for Public Shareholders upon potential dissolution is approximately $10.49 as of December 31, 2025[85]. - If the Proposed Business Combination is not completed by November 4, 2026, Public Shares will be redeemed for a pro rata portion of the funds in the Trust Account[80]. - A total of 8,120,834 Public Shares, or 32.5% of the 25,000,000 Public Shares sold in the IPO, must be voted in favor of the initial business combination for it to be approved[96]. - If the aggregate cash consideration for redemptions exceeds the cash available, the initial business combination will not be completed, and all submitted shares will be returned[101]. - Shareholders holding more than 15% of the shares sold in the offering will be restricted from seeking redemption rights without prior consent[102]. - The company will conduct redemptions in conjunction with a proxy solicitation or a tender offer, depending on the circumstances[95][97]. - As of the EGM held on March 12, 2026, Public Shareholders holding 22,550,551 Public Shares, approximately 90.3% of the outstanding Public Shares, exercised their redemption rights[118]. - The Sponsor owned 25.9% of the issued and outstanding ordinary shares as of December 31, 2025, and has agreed to vote in favor of any alternative business combination[116]. Financial and Operational Considerations - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from various reporting requirements[107]. - The company has received a tax exemption undertaking from the Cayman Islands government for a period of 20 years, exempting it from certain taxes on profits and income[106]. - The company may not have full-time employees until the completion of its initial business combination, currently anticipated for March 16, 2026[104]. - The company may face challenges in optimizing its capital structure due to the potential need for third-party financing if a significant number of shares are redeemed[119]. - The company may depend on loans from the Sponsor or management team to complete the Business Combination if the net proceeds of the IPO are insufficient[140]. - The company has agreed to indemnify its Sponsor, officers, and directors, but this may discourage shareholders from bringing lawsuits against them for breach of fiduciary duty[144]. - The company may incur substantial debt to complete an initial business combination, which could negatively impact financial condition and shareholder value[170]. - The complexity of tax obligations may increase post-business combination, potentially leading to adverse tax consequences for shareholders[193]. - The company may face significant financial and management resource burdens due to compliance with the Sarbanes-Oxley Act, particularly regarding internal controls[186]. - The management team has extensive experience in identifying and executing strategic investments globally, particularly in the healthcare sector[158]. Risks and Challenges - The company may face increased competition from other special purpose acquisition companies (SPACs) for attractive targets, potentially impacting acquisition terms[60]. - The company may face challenges if attempting to complete multiple business combinations simultaneously, which could increase costs and risks[174]. - The management team emphasizes the importance of identifying suitable candidates for initial business combinations, with a disciplined approach to due diligence and execution[53]. - The company may not be able to maintain control of the target business after the initial business combination, impacting operational effectiveness[189]. - The management of the target business may not possess the necessary skills to operate a public company, potentially affecting profitability[190]. - The company may face challenges in enforcing rights under foreign laws, risking significant business losses[208]. - Political events in foreign countries could negatively affect business operations and assets[202]. - The company may face additional risks associated with cross-border operations if the target business operates outside the United States[197]. - Changes in laws or regulations may adversely affect the company's ability to negotiate and complete the initial business combination[155]. - The company may incur additional expenses due to compliance with evolving regulatory measures, which could impact its results of operations[156]. Regulatory and Compliance Issues - The SEC's guidance in 2024 indicates that the determination of whether a SPAC is an "investment company" requires individualized analysis based on various factors[151]. - The company may be required to provide financial statements in accordance with GAAP or IFRS, which could limit the pool of potential target businesses[184]. - Regulatory review by CFIUS may impact the ability to complete the Proposed Business Combination, potentially delaying or prohibiting it[181]. - The process of government review could be lengthy, potentially leading to liquidation if approvals are not obtained in time[183]. - The absence of a specified maximum redemption threshold may enable the completion of a business combination even if a majority of shareholders disagree[176]. - There is no requirement for an independent valuation opinion for alternative business combinations, potentially affecting shareholder confidence[163]. Management and Governance - Conflicts of interest may arise due to officers and directors allocating time to other business activities[214]. - The company does not have policies to prevent officers and directors from engaging in similar business activities, leading to potential conflicts[217]. - The management team may negotiate employment agreements that could create conflicts of interest in business combinations[213]. - The company may not seek to extend the deadline for the initial business combination, which could lead to the Public Rights becoming worthless if not completed[128]. - The company may engage in private transactions to purchase Public Shares or Rights to influence shareholder votes on the proposed business combination[129].

Financial Results - AMREP Corporation reported its results for the three and nine month periods ended January 31, 2026[5]. - The press release detailing the financial results was issued on March 12, 2026[5]. - The financial statements and exhibits are included in the Form 8-K filing[7]. Company Information - The company is listed on the New York Stock Exchange under the symbol AXR[3]. - The report does not indicate whether AMREP Corporation is an emerging growth company[4].

Financial Performance - Fourth quarter net revenue was $118.8 million, and full year net revenue was $319.9 million, reflecting a decline from the previous year [2]. - Net income for the fourth quarter was $17.6 million, while full year net income was $15.7 million [2]. - Adjusted EBITDA for the fourth quarter was $28.1 million, and for the full year, it was $40.1 million [2]. - Net income for the year ended December 31, 2025, was $15,731 million, slightly down from $16,183 million in 2024, representing a decrease of about 3% [29]. - Adjusted EBITDA for the year ended December 31, 2025, was $40,098 million, down from $56,417 million in 2024, a decline of approximately 29% [31]. Growth Projections - The company expects full year 2026 net revenues to be between $335 million and $355 million, representing 5% to 11% year-over-year growth [10]. - Adjusted EBITDA for 2026 is projected to be between $44 million and $48 million, indicating a 10% to 20% year-over-year growth [10]. Operational Efficiency - The company is focused on innovation and operational efficiency to drive growth and capitalize on market recovery opportunities [7]. - The anticipated launch of Grand Theft Auto VI in late 2026 is expected to significantly boost gaming engagement and accessory demand [12]. Balance Sheet Changes - Total assets decreased from $298,861 million in 2024 to $269,054 million in 2025, a decline of approximately 10% [26]. - Total current liabilities decreased from $123,672 million in 2024 to $87,677 million in 2025, a reduction of approximately 29% [26]. - Stockholders' equity increased from $120,604 million in 2024 to $128,498 million in 2025, an increase of about 7% [26]. - Cash and cash equivalents at the end of the period rose to $16,963 million in 2025 from $12,995 million in 2024, an increase of about 31% [29]. - The company reported a loss on extinguishment of debt amounting to $1,921 million in 2025, compared to no such loss in 2024 [29]. - The company acquired a business net of cash acquired for $2,515 million in 2025, contrasting with a cash outflow of $77,294 million for acquisitions in 2024 [29]. - The company’s accounts receivable improved, with a net increase of $17,090 million in 2025 compared to a decrease of $15,624 million in 2024 [29]. Shareholder Actions - The company repurchased $19 million of shares during 2025 at an average price of $14.09 per share, totaling approximately 1,345,800 shares [5]. Debt and Cash Flow - As of December 31, 2025, the company had net debt of $68.1 million, with expectations for a substantial decline in the first quarter [9]. - Net cash provided by operating activities significantly increased to $35,458 million in 2025 from $5,761 million in 2024, marking a growth of over 500% [29]. Margin Analysis - Gross margin improved to 40.1% in the fourth quarter and 37.3% for the full year, marking year-over-year increases of 310 and 270 basis points respectively [5].

Financial Performance - Net earnings for Q1 2026 were $229 million, or $0.93 per diluted share, down from $520 million, or $1.96 per diluted share in Q1 2025[4]. - Total revenues decreased by 13% to $6.6 billion, primarily due to an 8% drop in average sales price and a 5% decrease in home deliveries[7]. - Homebuilding revenues for Q1 2026 totaled $6,298,563, a decrease of 13.5% from $7,283,870 in Q1 2025[22]. - Financial Services revenues decreased to $215,555 in Q1 2026 from $277,077 in Q1 2025, with operating earnings of $91,313, down from $143,483[22]. - Financial Services operating earnings fell to $91 million from $143 million in the previous year, attributed to lower lock volume[10]. Home Sales and Orders - New orders increased by 1% year over year to 18,515 homes, while backlog stood at 15,588 homes valued at $6.0 billion[3]. - New orders increased to 18,515 homes in Q1 2026, compared to 18,355 homes in Q1 2025, with a total dollar value of $7,139,386, a decrease of 3.9% from $7,430,732[24]. - Backlog increased to 15,588 homes in Q1 2026, with a dollar value of $6,040,767, up from 13,145 homes valued at $5,766,084 in Q1 2025[25]. - Total home deliveries decreased to 16,863 homes in Q1 2026 from 17,834 homes in Q1 2025, with a total dollar value of $6,344,795, down 12.9% from $7,281,529[23]. Homebuilding Operations - Homebuilding operating earnings were $373 million with a gross margin of 15.2% and net margin of 5.3%[3]. - Homebuilding net margins for Q1 2026 were $328,143, down 55.9% from $743,910 in Q1 2025[22]. - Average sales price for homes delivered in Q1 2026 was $374,000, down from $408,000 in Q1 2025[7]. - Construction costs improved by over 2.5% in Q1 2026 and have decreased by 12% over the last two years[5]. Cash and Assets - Cash and cash equivalents decreased to $2,085,384 as of February 28, 2026, from $3,441,324 as of November 30, 2025[27]. - Total assets decreased to $33,210,342 as of February 28, 2026, from $34,430,437 as of November 30, 2025[27]. - Net homebuilding debt increased to $1,980,075 as of February 28, 2026, compared to $643,362 as of November 30, 2025[29]. - Homebuilding debt to total capital ratio remained stable at 15.7% for both February 28, 2026, and November 30, 2025[29]. Shareholder Actions - The company repurchased 2 million shares for $237 million at an average price of $118.54 per share[14]. Future Outlook - The company expects to deliver approximately 20,000 to 21,000 homes in Q2 2026, with gross margin improving to 15.5% to 16%[5]. - Selling, general and administrative expenses as a percentage of revenues increased to 9.8% from 8.5% year over year[9].

Financial Performance - Net earnings for Q1 2026 were $229 million, or $0.93 per diluted share, down from $520 million, or $1.96 per diluted share in Q1 2025[4]. - Total revenues decreased by 13% to $6.6 billion, primarily due to an 8% drop in average sales price and a 5% decrease in home deliveries[7]. - Homebuilding operating earnings fell to $373,028 in Q1 2026, a decline of 54.0% compared to $809,273 in Q1 2025[22]. - Financial Services operating earnings fell to $91 million from $143 million in the previous year, attributed to lower lock volume[10]. - Cash and cash equivalents decreased to $2,085,384 in Q1 2026 from $3,441,324 in Q4 2025[27]. Home Sales and Orders - New orders increased by 1% year over year to 18,515 homes, while backlog stood at 15,588 homes valued at $6.0 billion[3]. - Total deliveries in Q1 2026 were 16,863 homes, down 5.4% from 17,834 homes in Q1 2025, with a total dollar value of $6,344,795[23]. - New orders increased to 18,515 homes in Q1 2026, up 0.9% from 18,355 homes in Q1 2025, with a total dollar value of $7,139,386[24]. - Backlog as of February 28, 2026, reached 15,588 homes, an increase of 18.6% from 13,145 homes in February 2025, with a total dollar value of $6,040,767[25]. Homebuilding Costs and Margins - Homebuilding revenues for Q1 2026 totaled $6,298,563, a decrease of 13.5% from $7,283,870 in Q1 2025[22]. - Total homebuilding costs and expenses decreased to $5,970,420 in Q1 2026, down 8.7% from $6,539,960 in Q1 2025[22]. - Homebuilding operating earnings were $373 million with a gross margin of 15.2% and net margin of 5.3%[3]. - The company expects to deliver approximately 20,000 to 21,000 homes in Q2 2026, with gross margin improving to 15.5% to 16%[5]. - Average sales price for homes delivered in Q1 2026 was $374,000, down from $408,000 in Q1 2025[7]. - Average sales price for homes delivered in Q1 2026 was $374,000, down 8.3% from $408,000 in Q1 2025[23]. - Selling, general and administrative expenses as a percentage of home sales increased to 9.8% from 8.5% year over year[9]. - Construction costs improved by over 2.5% in Q1 2026 and decreased by 12% over the last two years[5]. Debt and Share Repurchase - Homebuilding debt stood at $4,065,459 as of February 28, 2026, slightly down from $4,084,686 at the end of November 2025[29]. - Net homebuilding debt to total capital ratio improved to 8.3% in Q1 2026, compared to 2.8% in Q4 2025[29]. - The company repurchased 2 million shares for $237 million at an average price of $118.54 per share[14].

Financial Performance - Revenue for Q4 2025 was $58.9 million, a 15.8% decrease compared to Q4 2024, and a 7.0% decrease from Q3 2025[5] - Gross profit for Q4 2025 was $9.1 million, a 15.1% decrease compared to Q4 2024, and a 20.6% decrease from Q3 2025[5] - GAAP net loss for Q4 2025 was $1.7 million, an improvement from a net loss of $9.5 million in Q4 2024[5] - Adjusted EBITDA for Q4 2025 was $2.1 million, compared to $1.7 million in Q4 2024[5] - Total revenue for fiscal year 2025 was $250.2 million, a 13.3% decrease compared to 2024[5] - Gross profit for fiscal year 2025 was $42.5 million, a 14.9% decrease compared to 2024[5] - GAAP net loss for fiscal year 2025 was $15.4 million, consistent with a net loss of $15.1 million in 2024[5] Debt and Financial Flexibility - Debt was reduced by $13.2 million in 2025, representing a 16.4% reduction from December 31, 2024[5] - The ABL credit facility was refinanced with Texas Capital Bank, providing additional financial flexibility through 2027[6] Asset and Liability Changes - Total current assets decreased from $75,139 million in 2024 to $51,198 million in 2025, a decline of approximately 31.9%[18] - Cash and cash equivalents increased significantly from $396 million in 2024 to $1,014 million in 2025, representing a growth of 156.6%[18] - Accounts receivable decreased from $62,252 million in 2024 to $49,010 million in 2025, a reduction of about 21.3%[18] - Total liabilities decreased from $121,489 million in 2024 to $105,039 million in 2025, a decline of approximately 13.5%[18] - Current liabilities decreased from $44,391 million in 2024 to $39,527 million in 2025, a reduction of about 11.5%[18] - Notes payable decreased from $76,265 million in 2024 to $63,999 million in 2025, a decline of approximately 16.0%[18] Equity and Deficit - Stockholders' equity decreased from $54,156 million in 2024 to $40,512 million in 2025, a drop of about 25.2%[18] - Additional paid-in capital increased from $179,246 million in 2024 to $180,984 million in 2025, a rise of approximately 1.0%[18] - The accumulated deficit increased from $125,111 million in 2024 to $140,493 million in 2025, reflecting a worsening of about 12.3%[18] - Total assets decreased from $175,645 million in 2024 to $145,551 million in 2025, a decline of approximately 17.1%[18] Business Development - The company launched significant expansions with existing customers and onboarded a new full-service restaurant customer[5]

Financial Performance - As of December 31, 2025, the company had cumulative losses of CHF 311.8 million, with a negative net result attributable to shareholders of CHF 61.7 million for the year ended December 31, 2025[38]. - The company has invested most of its resources in developing product candidates and has never generated any revenue from product sales since its inception in 2004[40]. - The company has incurred significant operating losses primarily due to research and development costs, with expectations of continued losses in future periods[39]. - The company anticipates that its existing cash and cash equivalents will fund operations into 2028, but this estimate is based on assumptions that may prove incorrect[46]. Funding and Capital Requirements - The company expects to incur significant additional funding needs to complete the development and commercialization of its product candidates, with a sales agreement in place for gross sales proceeds of up to $100.0 million[44]. - Future capital requirements will depend on various factors, including the ability to raise additional funds, which may be limited due to the company's status as a Swiss corporation[46]. - The company may need to relinquish rights to technologies or product candidates if it cannot secure necessary funding, which could adversely affect its business prospects[51]. Clinical Development and Regulatory Approval - All product candidates are in preclinical or various stages of clinical development, with no candidates having received marketing approval from the FDA or other regulatory authorities[66]. - The process of obtaining regulatory approval is lengthy and expensive, often taking many years and requiring substantial evidence from clinical trials[67]. - Clinical trials are subject to delays due to various factors, including regulatory approvals, patient recruitment, and compliance with protocols, which can significantly impact costs and timelines[58][61]. - The company faces risks associated with conducting clinical trials in multiple countries, including adherence to protocols and additional regulatory requirements[63][64]. - The company must demonstrate safety, purity, and efficacy through extensive preclinical studies and clinical trials to obtain regulatory approvals[67]. Risks and Challenges in Clinical Trials - The company may face delays in clinical trials and regulatory approvals due to health epidemics, which could adversely impact its business operations[47]. - Delays in clinical trials can harm the commercial prospects of product candidates and may allow competitors to bring products to market first[61]. - Positive results from early preclinical studies do not guarantee success in later stages of development or regulatory approval[70][71]. - Adverse side effects from product candidates could delay or prevent marketing approval, affecting the commercial profile and potential revenue[82]. - Patient enrollment in clinical trials is critical, and difficulties in recruitment could delay product development and approval[90]. Market and Competitive Landscape - The company faces significant competition from established pharmaceutical and biotechnology companies, which may limit commercial opportunities[89]. - Market acceptance of the company's products will depend on various factors, including physician and patient perceptions, reimbursement availability, and competitive advantages over alternative treatments[145]. - The company may face competition from biosimilars sooner than anticipated due to the Biologics Price Competition and Innovation Act, which allows for abbreviated approval pathways[149]. Regulatory Environment and Compliance - The company is subject to stringent U.S. and foreign data privacy laws, which could lead to significant penalties and operational disruptions if compliance is not maintained[188]. - The company faces significant civil, criminal, and administrative penalties if found in violation of healthcare laws and regulations[125]. - Compliance with manufacturing regulations requires significant resources, and failure to meet these requirements could lead to enforcement actions and adversely affect product supplies[220]. Intellectual Property and Patents - The company faces challenges in obtaining and maintaining patents and intellectual property rights, which are crucial for competitive advantage and commercial success[226]. - The patent prosecution process is expensive and complex, with uncertainty regarding the issuance and scope of patents, potentially impacting the company's market share[227]. - The validity and enforceability of the company's patent rights are uncertain, which could affect the commercial value of its technology[229]. Collaboration and Partnerships - The company is dependent on collaborative partners for the development and commercialization of its research programs and product candidates, which could adversely affect its business if these relationships are not maintained[212]. - The company currently has collaborative research relationships with institutions such as the University of Bern and Orano Med, and discussions for potential partnerships with various pharmaceutical companies are ongoing[213]. - The company faces significant competition in securing collaborative partners, which may impact its ability to negotiate timely and favorable agreements[215]. Manufacturing and Supply Chain Risks - The company relies on third-party manufacturers (CMOs) for producing clinical drug supplies and lacks internal manufacturing capabilities, increasing risks associated with supply chain disruptions[218]. - The company relies on single-source unaffiliated third-party suppliers for certain raw materials, which poses a risk to production continuity if these suppliers fail to deliver[185]. - Manufacturing process failures could result in product defects, recalls, and insufficient inventory, adversely affecting the company's ability to supply approved products[183].

Financial Performance - Net sales for the third quarter of fiscal 2026 decreased 0.9% to $264.6 million from $267.1 million in the same period of fiscal 2025, primarily due to a 4.8% decrease in case volume[47]. - For the first nine months of fiscal 2026, net sales decreased 0.5% to $883.4 million, with a 4.9% decrease in case volume partially offset by a 4.7% increase in average selling price per case[53]. Gross Profit and Margins - Gross profit for the third quarter of fiscal 2026 increased to $99.6 million, with a gross margin of 37.6%, up from 37.1% in the prior year, driven by a 4.4% increase in average selling price per case[48]. - Gross profit for the first nine months of fiscal 2026 increased to $334.3 million, with a gross margin of 37.8%, up from 37.3% in the prior year[54]. Expenses - Selling, general and administrative expenses remained constant at $48.4 million, but as a percentage of net sales, they increased to 18.3% from 18.1% year-over-year[49]. Cash Position and Working Capital - The company's cash position increased by $120.1 million for the first nine months of fiscal 2026, compared to a decrease of $177.8 million in the same period of fiscal 2025[58]. - Working capital increased by $149.6 million to $416.0 million as of January 31, 2026, with a current ratio of 4.4 to 1 compared to 2.9 to 1 at May 3, 2025[63]. Operating Activities - Net cash provided by operating activities for the first nine months of fiscal 2026 was $135.7 million, down from $146.6 million in the prior year[59]. Cost of Sales - The average cost of sales per case increased by 3.4% for the third quarter and 3.7% for the first nine months of fiscal 2026[48][54]. Interest Income - Interest income for the third quarter of fiscal 2026 was $2.8 million, up from $1.4 million in the same period of fiscal 2025, attributed to increased average invested balances[50].

TRA Payments and Tax Implications - Payments under the TRA may exceed 85% of actual cash tax savings, potentially impacting liquidity [224] - TRA payments depend on future tax savings and are calculated based on the market value of Class A Common Stock at the time of redemption [222] - If obligations under the TRA accelerate due to breaches or changes in control, payments could be required in a lump sum based on anticipated future tax benefits [224] - The ability to make TRA payments is contingent on WMH LLC's capacity to distribute funds, with deferred payments accruing interest if not made [225] Cannabis Industry Risks - Cannabis remains a prohibited substance under federal law, posing risks to the business plan and operations [226] - The U.S. Supreme Court affirms federal authority to regulate cannabis, regardless of state legality [227] - The Sessions Memo allows federal prosecutors discretion in enforcing cannabis laws, which could affect state-legal companies [228] - The Joyce Amendment prohibits DOJ from using funds to prevent states from implementing medical-use cannabis laws, but future funding may not be guaranteed [229] - Financial transactions involving cannabis proceeds may lead to prosecution under federal money laundering statutes [231] - Changes in federal enforcement posture regarding cannabis could significantly impact business operations and financial results [236] - The cannabis-related businesses face significant challenges in accessing banking services due to federal-level illegality, which could materially affect their operations and financial condition [241] - Cannabis businesses must undergo extensive client due diligence, which can be time-consuming and costly, potentially creating barriers to financial services [243] - The company does not sell cannabis products but may still face banking restrictions due to its association with the cannabis industry, impacting its ability to manage operations and accept payments [245] - The FDA may impose regulations on adult-use and medical-use cannabis, which could negatively affect the cannabis industry and, consequently, the company's financial condition [252] - The hemp-derived product market is projected to reach $3.5 billion in sales for 2024, with potential growth to $4.4 billion by 2029, posing competition to the cannabis industry [254] - The regulatory environment surrounding hemp-derived products is volatile, which creates uncertainty for cannabis clients and could adversely impact their profitability [254] - Hemp-derived THC products are increasingly available through unlicensed channels, potentially drawing consumers away from cannabis-derived products [257] - The company may face significant management distraction and expenses if clients are found in violation of money laundering statutes, which could disrupt operations [247] - The inability of clients to access banking services may hinder the company's ability to conduct business and receive timely payments [244] - The conduct of third parties, including clients, may jeopardize the company's regulatory compliance and expose it to potential legal actions [251] Legal and Regulatory Compliance - Section 230(c)(1) of the Communications Decency Act may provide immunity from civil and state criminal liability, but its applicability is uncertain, posing legal and operational risks [258] - Cannabis businesses face strict marketing regulations in various states, potentially impacting demand for listing and marketing services, which could result in revenue loss [259] - Section 280E of the Internal Revenue Code restricts cannabis businesses from deducting expenses beyond the cost of goods sold, adversely affecting profitability and demand for services [260] - Cannabis businesses may be subject to civil asset forfeiture, which could negatively impact their operations and the company's revenue if clients face asset seizures [263] - Difficulty in obtaining insurance due to involvement in the cannabis industry may expose the company to additional risks and financial liabilities [264] - Changes in laws and regulations may create uncertainty and increase compliance costs, potentially harming the company's business [289] Financial Performance and Market Dynamics - Concentration of ownership among executive officers and directors, owning approximately 19.9% of Class A and Class V Common Stock, may limit new investors' influence on corporate decisions [268] - The company does not anticipate declaring any cash dividends in the foreseeable future, which may affect investor returns [271] - Sales of a substantial number of shares in the public market could significantly reduce the market price of Class A Common Stock, regardless of business performance [275] - The exercise of Public Warrants or other securities will result in dilution for existing shareholders and increase the number of shares available for resale, potentially affecting market price [276] - The company may issue additional shares of Class A Common Stock or preferred stock, which could significantly dilute the equity interests of existing investors [277] - The Class A Common Stock has been subject to volatility, with trading prices potentially declining due to various factors beyond the company's control [278] - The company has faced compliance issues with Nasdaq listing standards, including a minimum closing bid price requirement of $1.00 per share, which was not met for 30 consecutive trading days [280] - The company received a compliance period of 180 days to regain compliance with Nasdaq's minimum bid price requirement, which was successfully achieved [280] - Economic downturns may adversely affect the company's business, particularly impacting small and medium-sized clients who may struggle with access to capital [283] - Increased costs and administrative burdens have arisen from operating as a public company, diverting resources from business expansion [287] - The company has incurred costs related to restating financial statements due to errors in revenue recognition policies, which may continue to result in unanticipated expenses [290] - The company is exposed to risks of misconduct by employees and independent contractors, which could adversely affect its financial condition and operating results [292] - The trading market for the company's Class A Common Stock may be influenced by analysts' reports, and any adverse changes in recommendations could lead to a decline in stock price [294]